|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from C-terminus of human Flt-4 protein|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.6, with 1% BSA|
|Contains||<0.1% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
This antibody is predicted to react with canine, porcine and rat based on sequence homology.
Heat-mediated antigen retrieval is recommended prior to staining, using a 10mM citrate buffer, pH 6.0, for 10 minutes followed by cooling at room temperature for 20 min. Following antigen retrieval, incubate samples with primary antibody for 10 min at room temperature. A suggested positive control is placenta or breast carcinoma.
Three cell membrane receptor tyrosine kinases, Flt (also designated VEGF-R1), Flk-1 (also designated VEGF-R2) and Flt-4 (also designated VEGF-R3), putatively involved in the growth of endothelial cells, are characterized by the presence of seven immuno-globulin-like sequences in their extracellular domain. On the basis of structural similarity to Flt and Flk-1, it has been speculated that Flt-4 might represent a third receptor for eother VEGF or a VEGF-related ligand.
FLT41; fms-like tyrosine kinase 4; fms-related tyrosine kinase 4; PCL; tyrosine-protein kinase receptor FLT4; VEGFR3
FLT-4; FLT4; FLT41; LMPH1A; PCL; VEGFR-3; VEGFR3